Consensus of Chinese Orthopaedic Experts on Diagnosis and Treatment of Ankylosing Spondylitis

Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Department of Orthopaedic Surgery, Nanfang Hospital, Guangzhou, Arthritis Clinic & Research Center, Peking University People’s Hospital, Beijing, Department of Orthopaedics, Southwest Hospital, Third Military Medical University, Chongqing, Department of Orthopaedic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Department of Orthopaedics, Peking University Third Hospital, Beijing, Center for Osteonecrosis and Joint Preserving & Reconstruction, Department of Orthopaedic Surgery, China-Japan Friendship Hospital, Beijing, Department of Orthopaedics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Department of Orthopaedics, First Affiliated Hospital and Orthopaedic Institute of Soochow University, Suzhou, Department of Orthopaedics, General Hospital of Chinese People’s Liberation Army, Beijing, Department of Orthopaedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Department of Spine Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, and Department of Bone Oncology, Tianjin Hospital, Tianjin, China

[1]  S. Bae,et al.  Incidence of Tuberculosis Among Korean Patients with Ankylosing Spondylitis Who Are Taking Tumor Necrosis Factor Blockers , 2011, The Journal of Rheumatology.

[2]  Matthias Schneider,et al.  Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. , 2011, Rheumatology.

[3]  M. Dougados,et al.  The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. , 2011, Clinical and experimental rheumatology.

[4]  R. Burgos-Vargas,et al.  Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. , 2011, Arthritis and rheumatism.

[5]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[6]  M. Dougados,et al.  2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis , 2011, Annals of the rheumatic diseases.

[7]  Andreas Krause,et al.  Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial , 2011, Annals of the rheumatic diseases.

[8]  M. Dougados,et al.  Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE) , 2011, Annals of the rheumatic diseases.

[9]  J. Butera,et al.  Perioperative Management of Chronic Anticoagulation in Orthopaedic Surgery , 2010, The Journal of the American Academy of Orthopaedic Surgeons.

[10]  P. Kiely,et al.  BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. , 2010, Rheumatology.

[11]  Chinese specialist consensus on treatment of customary pain in orthopaedics , 2010, Orthopaedic surgery.

[12]  C. Gabay,et al.  Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. , 2010, Joint, bone, spine : revue du rhumatisme.

[13]  K. Ikari,et al.  Effect of total knee arthroplasty on disease activity in patients with established rheumatoid arthritis: 3-year follow-up results of combined medical therapy and surgical intervention , 2010, Modern rheumatology.

[14]  Takahiko Horiuchi,et al.  Transmembrane TNF-α: structure, function and interaction with anti-TNF agents , 2010, Rheumatology.

[15]  J. Braun,et al.  ASAS-Klassifikationskriterien für axiale Spondyloarthritis , 2009, Zeitschrift für Rheumatologie.

[16]  P. V. van Riel,et al.  Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.

[17]  W. Maksymowych.  Update on the treatment of ankylosing spondylitis , 2007, Therapeutics and clinical risk management.

[18]  J. Sieper,et al.  Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study , 2007, Annals of the rheumatic diseases.

[19]  N. Kadel,et al.  Perioperative Medication Management for the Patient With Rheumatoid Arthritis , 2006, The Journal of the American Academy of Orthopaedic Surgeons.

[20]  R. Moots,et al.  Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. , 2011, Clinical and experimental rheumatology.